Table 1.

ONC201 shows efficacy in breast cancer cells regardless of sensitivity to TRAIL

Cell lineONC201 GI50 (μmol/L)TRAIL GI50 (ng/mL)Subtype
MDA-MB-436∼100>1,000TNBC
HCC1937∼100>1,000TNBC
BT202>1,000TNBC
HCC13955>1,000TNBC
MDA-MB-3615>1,000TNBC
MDA-MB-4682250TNBC
SUM149PT2125TNBC
MDA-MB-2315250TNBC
SKBR34>1,000HER2 amplified
BT4745>1,000ER+, HER2 amplified
T47D6.25>1,000ER+
MCF712.5>1,000ER+
ZR-75-16.25>1,000ER+
  • NOTE: Breast cancer cells were treated with ONC201 for 72 hours or recombinant human TRAIL for 4 hours, and resulting dose–response curves were used to calculate GI50 values.